微小残存病変検査の世界市場レポート 2025年

微小残存病変検査の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR13.1％で29億6,000万米ドルに成長します。予測期間の成長は、がん罹患率の増加、治療の進歩、精密医療の動向、早期発見へのシフト、ヘルスケアシステムの統合などに起因します。予測期間の主な動向には、リキッドバイオプシーアプローチの統合、再発の早期発見への注力、臨床試験におけるMRD検査の拡大、小児がん領域での採用拡大、研究開発のための共同研究などがあります。

予想されるがん患者の増加が微小残存病変検査市場の成長を牽引します。がんは、制御不能な細胞増殖と体内拡散を特徴とし、主に微小残存病変検査-残存がん細胞を検出する高感度メソッド-によって診断・モニタリングされます。この検査はがんの早期予防に役立ち、微小残存病変検査市場の拡大に貢献しています。例えば、米国がん協会（American Cancer Society Inc.）は、2022年に米国で新たに190万人のがん患者が発生し、609,360人ががん関連で死亡すると推定しており、がんの管理における微小残存病変検査の重要な役割を強調しています。

個別化医療に対する需要の高まりが微小残存病変検査市場を促進すると予想されます。個別化医療は、遺伝、ライフスタイル、環境などの個人の特性に基づいてヘルスケア介入を調整し、より良い転帰のために治療を最適化します。微小残存病変検査はこの文脈で極めて重要であり、治療後の残存がん細胞を正確にモニタリングし、標的治療を促進します。2022年、食品医薬品局の医薬品評価研究センターは37の新規分子実体を承認し、治療用NMEの約34％、12に相当するものが個別化医療連合によって個別化医薬品に分類されました。このことは、個別化医療に対する需要の高まりと、それが微小残存病変検査市場の成長にプラスの影響を与えていることを浮き彫りにしています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界微小残存病変検査PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、制約）
• 最終用途産業の分析
• 世界の微小残存病変検査市場：成長率分析
• 世界の微小残存病変検査市場の実績：規模と成長, 2019-2024
• 世界の微小残存病変検査市場の予測：規模と成長, 2024-2029, 2034F
• 世界微小残存病変検査総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の微小残存病変検査市場テストの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• DNAベースの検査
• RNAベースのテスト
• 免疫学的検査
• 世界の微小残存病変検査市場：技術別、実績と予測, 2019-2024, 2024-2029F, 2034F
• フローサイトメトリー
• ポリメラーゼ連鎖反応（PCR）
• 次世代シーケンシング（NGS）
• その他のテクノロジー
• 世界の微小残存病変検査市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 造血悪性腫瘍
• 白血病
• リンパ腫
• 固形腫瘍
• その他のアプリケーション
• 世界の微小残存病変検査市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と専門クリニック
• 診断検査室
• 学術研究機関
• その他のエンドユーザー
• 世界の微小残存病変検査市場、DNA検査の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ポリメラーゼ連鎖反応（PCR）検査
• 次世代シーケンシング（NGS）
• デジタルPCR
• 世界の微小残存病変検査市場RNAベースのテストのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 逆転写PCR（RT-PCR）
• RNAシークエンシング
• 定量PCR（qPCR）
• 世界の微小残存病変検査市場、免疫学的検査のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• フローサイトメトリー
• 酵素免疫測定法（ELISA）
• 免疫組織化学

第7章 地域別・国別分析

• 世界の微小残存病変検査市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の微小残存病変検査市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 微小残存病変検査市場：競合情勢
• 微小残存病変検査市場：企業プロファイル
  • Natera Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Guardant Health Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Laboratory Corporation of America Holdings Overview, Products and Services, Strategy and Financial Analysis
  • QIAGEN NV Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bio-Techne Corporation
• Bio-Rad Laboratories Inc.
• Sysmex Corporation
• Exact Sciences Corporation
• GRAIL LLC
• Veracyte Inc.
• Cergentis B.V
• Mdxhealth SA
• NeoGenomics Laboratories Inc.
• Adaptive Biotechnologies
• OPKO Health Inc.
• Thermo Fisher Scientific Inc.
• Siemens Healthineers AG
• PerkinElmer Inc.
• Agilent Technologies Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 微小残存病変検査市場2029：新たな機会を提供する国
• 微小残存病変検査市場2029：新たな機会を提供するセグメント
• 微小残存病変検査市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Minimal residual disease testing involves highly sensitive tests aimed at detecting cancer cells that may persist in a patient's body after treatment. This type of testing is crucial for monitoring the effectiveness of cancer treatment and guiding future treatment strategies.

The main types of tests for minimal residual disease testing include DNA-based tests, RNA-based tests, and immunological tests. DNA-based testing, also known as genetic testing, is a medical examination designed to identify changes in chromosomes, genes, or proteins. Various technologies, such as flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS), and others, are employed in applications such as hematological malignancies, leukemia, lymphoma, solid tumors, and more. These tests are utilized by hospitals and specialty clinics, diagnostic laboratories, academic and research institutes, and other healthcare entities.

The minimal residual disease testing market research report is one of a series of new reports from The Business Research Company that provides minimal residual disease testing market statistics, including minimal residual disease testing industry global market size, regional shares, competitors with a minimal residual disease testing market share, detailed minimal residual disease testing market segments, market trends and opportunities, and any further data you may need to thrive in the minimal residual disease testing industry. This minimal residual disease testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The minimal residual disease testing market size has grown rapidly in recent years. It will grow from $1.59 billion in 2024 to $1.81 billion in 2025 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to advancements in cancer research, treatment monitoring needs, clinical evidence, regulatory support, patient outcome improvement.

The minimal residual disease testing market size is expected to see rapid growth in the next few years. It will grow to $2.96 billion in 2029 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to increasing cancer incidence, therapeutic advancements, precision medicine trends, shift toward early detection, healthcare system integration. Major trends in the forecast period include integration of liquid biopsy approaches, focus on early detection of relapse, expansion of MRD testing in clinical trials, increasing adoption in pediatric oncology, collaborations for research and development.

The anticipated increase in cancer cases is set to drive the growth of the minimal residual disease testing market. Cancer, characterized by uncontrolled cell growth and spread in the body, is primarily diagnosed and monitored through minimal residual disease testing-a highly sensitive method detecting residual cancer cells. This testing aids in the early-stage prevention of cancer, contributing to the expansion of the minimal residual disease testing market. For example, the American Cancer Society Inc. reported an estimated 1.9 million new cancer cases and 609,360 cancer-related deaths in the United States in 2022, emphasizing the critical role of minimal residual disease testing in managing cancer.

The growing demand for personalized medicine is expected to propel the minimal residual disease testing market. Personalized medicine tailors healthcare interventions based on individual characteristics such as genetics, lifestyle, and environment, optimizing treatments for better outcomes. Minimal residual disease testing is crucial in this context, precisely monitoring residual cancer cells post-treatment to facilitate targeted therapies. In 2022, the Food and Drug Administration's Center for Drug Evaluation and Research approved 37 new molecular entities, and approximately 34% of therapeutic NMEs, equivalent to 12, were classified as personalized medicines by the Personalized Medicine Coalition. This highlights the increasing demand for personalized medicine and its positive impact on the growth of the minimal residual disease testing market.

Product innovation emerges as a prominent trend in the minimal residual disease testing market, with major companies introducing new solutions to maintain their market positions. Twist Bioscience, a US-based synthetic biology and genomics company, launched the Twist MRD Panel in 2022, aiming to advance research and development in minimal residual disease detection in cancer screening. This customizable panel of genes is designed to detect very low levels of residual cancer cells in a patient's blood, offering flexibility and integration into next-generation sequencing workflows.

Major companies in the minimal residual disease testing market are also focusing on cancer research testing solutions to enhance detection sensitivity, improve treatment monitoring, and advance precision medicine approaches. For instance, Integrated DNA Technologies (IDT), a US-based genomic solutions provider, introduced the IDT Archer FUSIONPlex Core Solid Tumor Panel in April 2023. This enhanced cancer research testing solution simplifies fusion detection and variant calling in solid tumors, providing researchers with a scalable, user-friendly solution that saves time and resources.

In April 2023, Quest Diagnostics, a U.S.-based clinical laboratory, acquired Haystack Oncology. This acquisition aims to enhance personalized cancer care through Haystack's liquid biopsy technology, which detects residual or recurring cancer by identifying circulating tumor DNA (ctDNA) in the bloodstream. This method prioritizes early and accurate detection of cancer recurrence, aiding in treatment decisions and improving patient outcomes. Ultimately, this technology facilitates more effective management of cancer treatment. Haystack Oncology, Inc. is a U.S.-based biotechnology company.

Major companies operating in the minimal residual disease testing market include Natera Inc., Guardant Health Inc., Laboratory Corporation of America Holdings, QIAGEN NV, F. Hoffmann-La Roche Ltd., Bio-Techne Corporation, Bio-Rad Laboratories Inc., Sysmex Corporation, Exact Sciences Corporation, GRAIL LLC, Veracyte Inc., Cergentis B.V, Mdxhealth SA, NeoGenomics Laboratories Inc., Adaptive Biotechnologies, OPKO Health Inc., Thermo Fisher Scientific Inc., Siemens Healthineers AG, PerkinElmer Inc., Agilent Technologies Inc., ArcherDx Inc., Asuragen Inc., Becton, Dickinson and Company, Cepheid Inc., Fluidigm Corporation, Illumina Inc., Invitae Corporation, Janssen Diagnostics LLC, Luminex Corporation, Menarini Silicon Biosystems S.p.A.

North America was the largest region in the minimal residual disease testing market in 2024. The regions covered in the minimal residual disease testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the minimal residual disease testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The minimal residual disease testing market includes revenues earned by entities by providing services such as peripheral blood cell testing, sequencing testing, high-throughput sequencing testing, and methylation sequencing testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Minimal Residual Disease Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on minimal residual disease testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for minimal residual disease testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The minimal residual disease testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Test Type: DNA - Based Test; RNA- Based Test; Immunological Test
• 2) By Technology: Flow Cytometry; Polymerase Chain Reaction (PCR); Next-Generation Sequencing (NGS); Other Technologies
• 3) By Application: Hematological Malignancies; Leukemia; Lymphoma; Solid Tumors; Other Application
• 4) By End User: Hospitals And Specialty Clinics; Diagnostic Laboratories; Academic And Research Institutes; Other End Users
• Subsegments:
• 1) By DNA-Based Test: Polymerase Chain Reaction (PCR) Tests; Next-Generation Sequencing (NGS); Digital PCR
• 2) By RNA-Based Test: Reverse Transcription PCR (RT-PCR); RNA Sequencing; Quantitative PCR (qPCR)
• 3) By Immunological Test: Flow Cytometry; Enzyme-Linked Immunosorbent Assay (ELISA); Immunohistochemistry
• Companies Mentioned: Natera Inc.; Guardant Health Inc.; Laboratory Corporation of America Holdings; QIAGEN NV; F. Hoffmann-La Roche Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Minimal Residual Disease Testing Market Characteristics

3. Minimal Residual Disease Testing Market Trends And Strategies

4. Minimal Residual Disease Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Minimal Residual Disease Testing Growth Analysis And Strategic Analysis Framework

• 5.1. Global Minimal Residual Disease Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Minimal Residual Disease Testing Market Growth Rate Analysis
• 5.4. Global Minimal Residual Disease Testing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Minimal Residual Disease Testing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Minimal Residual Disease Testing Total Addressable Market (TAM)

6. Minimal Residual Disease Testing Market Segmentation

• 6.1. Global Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• DNA - Based Test
• RNA- Based Test
• Immunological Test
• 6.2. Global Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Flow Cytometry
• Polymerase Chain Reaction (PCR)
• Next-Generation Sequencing (NGS)
• Other Technologies
• 6.3. Global Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hematological Malignancies
• Leukemia
• Lymphoma
• Solid Tumors
• Other Application
• 6.4. Global Minimal Residual Disease Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Specialty Clinics
• Diagnostic Laboratories
• Academic and Research Institutes
• Other End Users
• 6.5. Global Minimal Residual Disease Testing Market, Sub-Segmentation Of DNA-Based Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Polymerase Chain Reaction (PCR) Tests
• Next-Generation Sequencing (NGS)
• Digital PCR
• 6.6. Global Minimal Residual Disease Testing Market, Sub-Segmentation Of RNA-Based Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Reverse Transcription PCR (RT-PCR)
• RNA Sequencing
• Quantitative PCR (qPCR)
• 6.7. Global Minimal Residual Disease Testing Market, Sub-Segmentation Of Immunological Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Flow Cytometry
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Immunohistochemistry

7. Minimal Residual Disease Testing Market Regional And Country Analysis

• 7.1. Global Minimal Residual Disease Testing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Minimal Residual Disease Testing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Minimal Residual Disease Testing Market

• 8.1. Asia-Pacific Minimal Residual Disease Testing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Minimal Residual Disease Testing Market

• 9.1. China Minimal Residual Disease Testing Market Overview
• 9.2. China Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Minimal Residual Disease Testing Market

• 10.1. India Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Minimal Residual Disease Testing Market

• 11.1. Japan Minimal Residual Disease Testing Market Overview
• 11.2. Japan Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Minimal Residual Disease Testing Market

• 12.1. Australia Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Minimal Residual Disease Testing Market

• 13.1. Indonesia Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Minimal Residual Disease Testing Market

• 14.1. South Korea Minimal Residual Disease Testing Market Overview
• 14.2. South Korea Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Minimal Residual Disease Testing Market

• 15.1. Western Europe Minimal Residual Disease Testing Market Overview
• 15.2. Western Europe Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Minimal Residual Disease Testing Market

• 16.1. UK Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Minimal Residual Disease Testing Market

• 17.1. Germany Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Minimal Residual Disease Testing Market

• 18.1. France Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Minimal Residual Disease Testing Market

• 19.1. Italy Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Minimal Residual Disease Testing Market

• 20.1. Spain Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Minimal Residual Disease Testing Market

• 21.1. Eastern Europe Minimal Residual Disease Testing Market Overview
• 21.2. Eastern Europe Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Minimal Residual Disease Testing Market

• 22.1. Russia Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Minimal Residual Disease Testing Market

• 23.1. North America Minimal Residual Disease Testing Market Overview
• 23.2. North America Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Minimal Residual Disease Testing Market

• 24.1. USA Minimal Residual Disease Testing Market Overview
• 24.2. USA Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Minimal Residual Disease Testing Market

• 25.1. Canada Minimal Residual Disease Testing Market Overview
• 25.2. Canada Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Minimal Residual Disease Testing Market

• 26.1. South America Minimal Residual Disease Testing Market Overview
• 26.2. South America Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Minimal Residual Disease Testing Market

• 27.1. Brazil Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Minimal Residual Disease Testing Market

• 28.1. Middle East Minimal Residual Disease Testing Market Overview
• 28.2. Middle East Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Minimal Residual Disease Testing Market

• 29.1. Africa Minimal Residual Disease Testing Market Overview
• 29.2. Africa Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Minimal Residual Disease Testing Market Competitive Landscape And Company Profiles

• 30.1. Minimal Residual Disease Testing Market Competitive Landscape
• 30.2. Minimal Residual Disease Testing Market Company Profiles
  • 30.2.1. Natera Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Guardant Health Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Laboratory Corporation of America Holdings Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. QIAGEN NV Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Minimal Residual Disease Testing Market Other Major And Innovative Companies

• 31.1. Bio-Techne Corporation
• 31.2. Bio-Rad Laboratories Inc.
• 31.3. Sysmex Corporation
• 31.4. Exact Sciences Corporation
• 31.5. GRAIL LLC
• 31.6. Veracyte Inc.
• 31.7. Cergentis B.V
• 31.8. Mdxhealth SA
• 31.9. NeoGenomics Laboratories Inc.
• 31.10. Adaptive Biotechnologies
• 31.11. OPKO Health Inc.
• 31.12. Thermo Fisher Scientific Inc.
• 31.13. Siemens Healthineers AG
• 31.14. PerkinElmer Inc.
• 31.15. Agilent Technologies Inc.

32. Global Minimal Residual Disease Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Minimal Residual Disease Testing Market

34. Recent Developments In The Minimal Residual Disease Testing Market

35. Minimal Residual Disease Testing Market High Potential Countries, Segments and Strategies

• 35.1 Minimal Residual Disease Testing Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Minimal Residual Disease Testing Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Minimal Residual Disease Testing Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer